RAMM Pharma Corp. RAMM
CNSX
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 915.10K | 1.37M | 1.84M | 2.40M | 2.71M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 915.10K | 1.37M | 1.84M | 2.40M | 2.71M |
| Cost of Revenue | 373.20K | 839.60K | 1.29M | 1.79M | 2.06M |
| Gross Profit | 542.00K | 532.10K | 546.30K | 605.10K | 646.10K |
| SG&A Expenses | 3.56M | 3.54M | 3.54M | 3.78M | 5.57M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 54.30K | 53.20K | 55.50K | 58.10K | 83.70K |
| Total Operating Expenses | 3.98M | 4.43M | 4.89M | 5.63M | 7.71M |
| Operating Income | -3.07M | -3.06M | -3.05M | -3.24M | -5.00M |
| Income Before Tax | -6.53M | -6.28M | -6.16M | -6.39M | -9.65M |
| Income Tax Expenses | 7.70K | 7.70K | 73.70K | 10.90K | 9.10K |
| Earnings from Continuing Operations | -6.54 | -6.29 | -6.23 | -6.40 | -9.66 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.54M | -6.29M | -6.23M | -6.40M | -9.66M |
| EBIT | -3.07M | -3.06M | -3.05M | -3.24M | -5.00M |
| EBITDA | -2.78M | -2.74M | -2.64M | -2.73M | -4.53M |
| EPS Basic | -0.05 | -0.05 | -0.05 | -0.05 | -0.08 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| EPS Diluted | -0.05 | -0.05 | -0.05 | -0.05 | -0.08 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| Average Basic Shares Outstanding | 477.56M | 477.56M | 477.56M | 477.56M | 477.56M |
| Average Diluted Shares Outstanding | 477.56M | 477.56M | 477.56M | 477.56M | 477.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |